China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Other Businesses. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test kits and analyzers. The Radioactive Source Products segment sells medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization, and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities and related technical services. The Radiation Therapy Equipment and Related Services segment sells nuclear medical equipment and provides related maintenance services. The Other Businesses segment provides independent clinical laboratory services for nuclear technology industry applications and medical product applications; and provides radioactive source, medical nuclides, imported radiopharmaceuticals, nuclear instruments and devices, medical equipment and other products. In addition, the company provides irradiation service for sterilization; and research, development, production, and sales of irradiation modified materials. The company was incorporated in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation.
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. Meanwhile, the market is actually up 24% over the past year. Earnings are forecast to grow by 27% annually. Market details ›